Tetanus: the Forgotten Disease

Total Page:16

File Type:pdf, Size:1020Kb

Tetanus: the Forgotten Disease Kansas Journal of Medicine 2007 Tetanus: The Forgotten Disease Tetanus: The Forgotten Disease 1 Boutros El-Haddad, M.D. 1 Jill Hanrahan, M.D. Maha Assi, M.D. 1,2 1University of Kansas School of Medicine – Wichita Department of Internal Medicine 2Infectious Disease Consultants, Wichita, KS Introduction Tetanus was well known to the ancient tetanus immunoglobulin were given physicians of Egypt and Greece, but since intramuscularly and active immunization institution of the active immunization in was started. Although there was no active 1940, it has become an old forgotten disease wound infection, the patient was started on in developed countries. 1 Tetanus is a intravenous metronidazole. Muscle spasms nervous system disorder characterized by and rigidity were controlled with a prolonged contraction of the skeletal scheduled dose of intravenous diazepam. muscles. The disease is caused by Over the next three weeks, the patient’s tetanospasmin, a neurotoxin produced by the symptoms gradually improved, and she was anaerobic bacterium Clostridium tetani. discharged to a skilled nursing facility. Case Report Epidemiology A 74-year-old Caucasian female The incidence of tetanus in developed presented to the emergency department countries dropped dramatically since 1940 complaining of trismus. The patient had not mainly due to the widespread use of active been evaluated by a physician for several immunization. 1 Better hygiene and wound years. Her symptoms started 10 days prior care also have played a major role. The with difficulty opening her mouth, annual incidence of tetanus in the US has generalized muscle stiffness, and episodic fallen from 4 to 0.2 per million since 1947. 1 muscle spasms. She denied fever and chills, The decline in incidence was accompanied was not taking any medications, and had no by a decrease in mortality from 50 to 30%. history of alcohol or illicit drug use. She did Between 1998 and 2000, the annual not remember ever receiving tetanus incidence of tetanus was 0.16 cases/million vaccination. representing an average of 43 cases per On physical examination, the patient was year. 2 The majority of cases were in patients unable to open her mouth more than 1 cm older than 60 years, reflecting the waning of and the masseter muscle was contracted. immunity with age or inadequate She had a generalized increase in muscle immunization of the elderly. 1 Injection drug tone and episodic painful muscle spasms abuse and the increase of non-immunized involving the entire body. Multiple scars immigrants are responsible for most cases of in different healing stages over the lower tetanus in younger individuals aged 25 to 59. extremities had been caused by scratches According to the CDC 2, 15% of cases of from her 13 cats. tetanus in the US occurred in intravenous The diagnosis of generalized tetanus was drug users. suspected. Five hundred units of human 9 Kansas Journal of Medicine 2007 Tetanus: The Forgotten Disease Acute injuries account for 70 to 80% of increased muscle tone and painful spasm. US cases; 23% of cases are associated with The autonomic nervous system also is chronic decubitus ulcers, gangrene, burns affected, manifested by a hypersympathetic and abcesses. 1 About 7% of cases have no state due to failure to inhibit the adrenal apparent source. Neonatal tetanus is rare in release of catecholamine. Tetanospasmin the US. 1,2 interferes with pre-synaptic acetylcholine Tetanus is common in developing release at the neuromuscular junction and countries. The worldwide incidence is about disinhibits sympathetic reflexes at the spinal 1,000,000 cases per year. 3,4 It is a major level.1 The inhibitory effect of cause of death especially in neonates. tetanospasmin is irreversible. Recovery Tetanus accounted for 300,000 deaths in requires the growth of new axonal nerve 2000, including 200,000 neonatal deaths.5 terminals in 4 to 6 weeks. Clostridium tetani produces another toxin called tetanolysin Pathogenesis and Pathology that apparently has no pathogenic role. 1 Clostridium tetani is an obligatory gram positive anaerobic bacillus. The bacteria are Clinical Features usually found in contaminated soil and The incubation period of tetanus usually animal gut in the sporiform phase. When lasts between 3 and 21 days with a range of these spores contaminate a wound, they one day to several months. 1 A correlation germinate under anaerobic conditions, exists between the distance of the injury transform into a rod-shaped bacterium, and from the CNS and the duration of the produce tetanospasmin. Tetanospasmin is incubation period.1,5 The closer the distance, an exotoxin produced by mature bacteria, the shorter the incubation period. Both the then cleaved intracellularly into light and incubation period and the time of onset heavy chains before exocytosis. The heavy (time from the first symptom to the first chain appears to mediate binding to cell generalized spasm) inversely correlate with surface and transport proteins, while the prognosis.1 light chain is responsible for the clinical Tetanus has four clinical forms: manifestations of tetanus. 1 generalized, localized, cephalic, and After its excretion, tetanospasmin gains neonatal. Generalized tetanus is the most entry into the central nervous system (CNS), common and severe. The generalized form both locally and distally, via the presynaptic typically starts with spasm of the masseter terminals of lower motor neurons. muscles, causing trismus or “lockjaw” and Tetanospasmin is transported intra-axonally increased tone of the orbicularis oris in a retrograde fashion to the cell body, the resulting in the characteristic “risus ventral horns of the spinal cord, and to the sardonicus”. The patient experiences diffuse motor nuclei of the cranial nerves where it spasms involving muscle groups in the neck, exerts its major pathogenic action. After back, abdomen, and extremities. These reaching the spinal cord and the brain stem, spasms are painful, intermittent, and tetanospasmin binds tightly and irreversibly unpredictable. They often are triggered by to specific receptors, inhibiting the release noise and light. of inhibitory neurotransmitters (glycine and Patients with generalized tetanus γ-amino-butyric acid) from presynaptic typically have symptoms of autonomic inhibitory neurons. overactivity that manifest as sweating, The net effect is the disinhibition of tachycardia, cardiac arrhythmia, labile motor excitatory neurons resulting in hypertension or hypotension, and fever. 10 Kansas Journal of Medicine 2007 Tetanus: The Forgotten Disease Respiratory muscles also are affected Differential Diagnosis causing periods of apnea. During Strychnine poisoning may produce a generalized tetanic spasms, patients clinical syndrome similar to tetanus. characteristically clench their fists, arch their Toxicologic screen of urine and blood back, flex their arms while extending their should be performed if a suspicious injection legs, and become apneic. 1 Death is due to is suspected or the history is not typical for respiratory failure or to autonomic tetanus (e.g., no injury or adequate dysfunction. Recurrent tetanus may occur if immunization). The treatment of tetanus the patient is not immunized since the and strychnine poisoning is similar. infection does not confer immunity. Trismus due to dental infection may be Recovery is typically 2 to 6 weeks. confused with cephalic tetanus. Drug Localized tetanus is usually a prodrome induced dystonia and malignant neuroleptic of the generalized form. It presents with syndrome can mimic tetanus. localized rigidity and spasm of a muscle group near the site of injury. Subsequently, Treatment patients develop generalized tetanus. In The treatment of patients with tetanus some cases, localized disease reflects partial requires a multidisciplinary approach in the immunity with resolution of the spasms intensive care unit.1 The mainstay of without generalization. 6 Cephalic tetanus is treatment consists of eliminating the source a form of localized tetanus involving the of toxin production, neutralizing unbound cranial nerves in a patient with head and toxin, and managing symptoms and neck injuries. 1 complications. Neonatal tetanus is related to the inadequate use of aseptic techniques in non- Halting toxin production immunized mothers. It usually occurs Wound debridement is important to within 14 days after birth. 1,7 Infants present eliminate the source of toxin production. with generalized weakness and failure to All foreign bodies, including spores and nurse, followed by rigidity and spasms. necrotic tissue, should be removed. Mortality exceeds 90%. Apnea and sepsis Metronidazole and penicillin G are the drugs are the leading causes of death. of choice, but studies have shown better outcomes with metronidazole. 1,8 Intravenous Diagnosis metronidazole should be given initially at a The diagnosis of tetanus is based on dose of 15mg/kg followed by 20 to 30 clinical symptoms and a high index of mg/kg/day intravenously for 7 to 14 days or suspicion in susceptible individuals.1 until there is no visible sign of active local Anaerobic cultures from the wound are infection.1 Alternatives include cefazolin, usually negative. A positive culture does cefuroxime, and ceftriaxone. not confirm the diagnosis. Anti-tetanus antibodies are undetectable in the majority Neutralizing of unbound toxin of patients with tetanus. However, the Tetanospasmin is bound irreversibly to presence of antibodies at low titer does not tissues and only unbound toxin is available
Recommended publications
  • Clostridium Species
    CLOSTRIDIUM SPECIES Prepared by Assit. Prof.Dr. Najdat B. Mahdi clostridia The clostridia are large anaerobic, gram-positive, motile rods. Many decompose proteins or form toxins, and some do both. Their natural habitat is the soil or the intestinal tract of animals and humans, where they live as harmless saprophytes. Among the pathogens are the organisms causing botulism, tetanus, gas gangrene, and pseudomembranous colitis diseases :The remarkable ability of clostridia to cause is attributed to their (1) ability to survive adverse environmental conditions through spore formation. (2) rapid growth in a nutritionally enriched, oxygen- deprived environment. (3) production of numerous histolytic toxins, and neurotoxins.and enterotoxins, Morphology & Identification . Spores of clostridia are usually wider than the diameter of the rods in which they are formed. In the various species, the spore is placed centrally, subterminally, or terminally. Most species of clostridia are motile and possess peritrichous flagella . Culture Clostridia are anaerobes and grow under anaerobic conditions; a few species are aerotolerant and will also grow in ambient air. Anaerobic culture conditions . In general, the clostridia grow well on the blood-enriched media used to grow anaerobes and on other media used to culture anaerobes as well. Clostridium botulinum Typical Organisms etiologic agents of botulism are a heterogeneous collection of large (0.6 to 1.4 × 3.0 to 20.2 μm), fastidious, sporeforming, anaerobic rods Clostridium botulinum Clostridium botulinum, which causes botulism, is worldwide in distribution; it is found in soil and occasionally in animal feces. Types are distinguished by the antigenic type of toxins they produce. Spores of the organism are highly resistant to heat, with standing 100 °C for several hours.
    [Show full text]
  • TETANUS in ANIMALS — SUMMARY of KNOWLEDGE Malinovská, Z
    DOI: 10.2478/fv-2020-0027 FOLIA VETERINARIA, 64, 3: 54—60, 2020 TETANUS IN ANIMALS — SUMMARY OF KNOWLEDGE Malinovská, Z., Čonková, E., Váczi, P. Department of Pharmacology and Toxicology University of Veterinary Medicine and Pharmacy in Košice, Komenského 73, 041 81 Košice Slovakia [email protected] ABSTRACT the effects of the neurotoxin. The treatment is difficult with an unclear prognosis. Tetanus is a neurologic non-transmissible disease (often fatal) of humans and other animals with a world- Key words: animal; Clostridium tetani; toxin; spasm; wide occurrence. Clostridium tetani is the spore produc- treatment ing bacillus which causes the bacterial disease. In deep penetrating wounds the spores germinate and produce a toxin called tetanospasmin. The main characteristic sign INTRODUCTION of tetanus is a spastic paralysis. A diagnosis is usually based on the clinical signs because the detection in the Of the clostridial neurotoxins, botulinum neurotoxin wound and the cultivation of C. tetani is very difficult. and tetanus neurotoxin are the most potent toxins [15]. Between animal species there is considerable variabili- Their extraordinary toxicity is caused by neurospecificity ty in the susceptibility to the bacillus. The most sensi- and metalloprotease activity, which results in the paralysis. tive animal species to the neurotoxin are horses. Sheep Tetanus is potentially a fatal disease and in some countries and cattle are less sensitive and tetanus in these animal it is still very active. Tetanus is a traumatic clostridiosis, species are less common. Tetanus in cats and dogs are an infection in humans and other animals with worldwide rare and dogs are less sensitive than cats.
    [Show full text]
  • NEUROCHEMISTRY A4b (1)
    NEUROCHEMISTRY A4b (1) Neurochemistry Last updated: April 20, 2019 CLASSIFICATION OF NEUROTRANSMITTERS ............................................................................................ 2 CATECHOLAMINES .................................................................................................................................. 3 NORADRENALINE (S. NOREPINEPHRINE, LEVARTERENOL) ..................................................................... 4 EPINEPHRINE .......................................................................................................................................... 6 DOPAMINE ............................................................................................................................................. 6 SEROTONIN (S. 5-HYDROXYTRYPTAMINE, 5-HT) ................................................................................... 8 HISTAMINE ............................................................................................................................................. 10 ACETYLCHOLINE ................................................................................................................................... 11 AMINO ACIDS ......................................................................................................................................... 13 GLUTAMATE, ASPARTATE .................................................................................................................... 13 Γ-AMINOBUTYRIC ACID (GABA) ........................................................................................................
    [Show full text]
  • ||||||||III US005562907A United States Patent (19 11 Patent Number: 5,562,907 Arnon 45 Date of Patent: Oct
    ||||||||III US005562907A United States Patent (19 11 Patent Number: 5,562,907 Arnon 45 Date of Patent: Oct. 8, 1996 54 METHOD TO PREVENT SIDE-EFFECTS AND Suen et al., "Clostridium argentinense, sp. nov: A Geneti INSENSTIVITY TO THE THERAPEUTIC cally Homogenous Group Composed of All Strains of Clostridium botulinum Toxin Type G and Some Nontoxi USES OF TOXINS genic Strains Previously Identified as Clostridium subtermi (76) Inventor: Stephen S. Arnon, 9 Fleetwood Ct., naleor Clostridium hastiforme' Int. J. System. Bacteriol. Orinda, Calif. 94563 (1988) 38(4):375-381. Van Ermengem, "Ueber einem neuen anaeroben Bacillus und seine Beziehungen zum Botulismus' Z. Hyg. Infektion (21) Appl. No.: 254.238 skrankh. (1897) 26:1-56. An English translation can be found in A New Anaerobic Bacillus and Its Relation to (22 Filed: Jun. 6, 1994 Botulism, Rev. Infect. Dis. (1979) 1(4):701-719. Koening et al., "Clinical and Laboratory Observations on Related U.S. Application Data Type E Botulism in Man' Medicine (1964) 43:517-545. Beller et al., “Repeated Type E Botulism in an Alaskan 63 Continuation-in-part of Ser. No. 62,110, May 14, 1993, Eskimo' N. Engl. J. Med. (1990) 322(12):855. abandoned. Schroeder et al., "Botulism from Fermented Trout' T. Nor ske Laegeforen (1962) 82:1084-1086. An English transla 30) Foreign Application Priority Data tion, beyond the title, is currently not available. Mar. 8, 1994 WO) WIPO ..................... PCT/US94/02521 Mandell et al., eds., Principles and Practice of Infectious Diseases, 3rd Edition, Churchill Livingstone, New York, (51 Int. Cl. .......................... A61K 39/08; A61K 39/38; (1990) pp.
    [Show full text]
  • Lllostridium Botulinum Neurotoxinl I H
    MICROBIOLOGICAL REVIEWS, Sept. 1980, p. 419-448 Vol. 44, No. 3 0146-0749/80/03-0419/30$0!)V/0 Lllostridium botulinum Neurotoxinl I H. WJGIYAMA Food Research Institute and Department ofBacteriology, University of Wisconsin, Madison, Wisconsin 53706 INTRODUCTION ........ .. 419 PATHOGENIC FORMS OF BOTULISM ........................................ 420 Food Poisoning ............................................ 420 Wound Botulism ............................................ 420 Infant Botulism ............................................ 420 CULTURES AND TOXIN TYPES ............................................ 422 Culture-Toxin Relationships ............................................ 422 Culture Groups ............................................ 422 GENETICS OF TOXIN PRODUCTION ......................................... 423 ASSAY OF TOXIN ............................................ 423 In Vivo Quantitation ............................................ 424 Infant-Potent Toxin ............................................ 424 Serological Assays ............................................ 424 TOXIC COMPLEXES ............................................ 425 Complexes 425 Structure of Complexes ...................................................... 425 Antigenicity and Reconstitution .......................... 426 Significance of Complexes .......................... 426 Nomenclature ........................ 427 NEUROTOXIN ..... 427 Molecular Weight ................... 427 Specific Toxicity ................... 428 Small Toxin ..................
    [Show full text]
  • Immune Effector Mechanisms and Designer Vaccines Stewart Sell Wadsworth Center, New York State Department of Health, Empire State Plaza, Albany, NY, USA
    EXPERT REVIEW OF VACCINES https://doi.org/10.1080/14760584.2019.1674144 REVIEW How vaccines work: immune effector mechanisms and designer vaccines Stewart Sell Wadsworth Center, New York State Department of Health, Empire State Plaza, Albany, NY, USA ABSTRACT ARTICLE HISTORY Introduction: Three major advances have led to increase in length and quality of human life: Received 6 June 2019 increased food production, improved sanitation and induction of specific adaptive immune Accepted 25 September 2019 responses to infectious agents (vaccination). Which has had the most impact is subject to debate. KEYWORDS The number and variety of infections agents and the mechanisms that they have evolved to allow Vaccines; immune effector them to colonize humans remained mysterious and confusing until the last 50 years. Since then mechanisms; toxin science has developed complex and largely successful ways to immunize against many of these neutralization; receptor infections. blockade; anaphylactic Areas covered: Six specific immune defense mechanisms have been identified. neutralization, cytolytic, reactions; antibody- immune complex, anaphylactic, T-cytotoxicity, and delayed hypersensitivity. The role of each of these mediated cytolysis; immune immune effector mechanisms in immune responses induced by vaccination against specific infectious complex reactions; T-cell- mediated cytotoxicity; agents is the subject of this review. delayed hypersensitivity Expertopinion: In the past development of specific vaccines for infections agents was largely by trial and error. With an understanding of the natural history of an infection and the effective immune response to it, one can select the method of vaccination that will elicit the appropriate immune effector mechanisms (designer vaccines). These may act to prevent infection (prevention) or eliminate an established on ongoing infection (therapeutic).
    [Show full text]
  • OBJECTIVES Spore-Forming Gram-Positive Bacilli: Clostridium
    PHARMACEUTICAL MICROBIOLOGY Assoc.Prof. Müjde Eryılmaz OBJECTIVES Spore-Forming Gram-Positive Bacilli: ❑ Clostridium • Clostridium perfringens • Clostridium tetani • Clostridium botulinum • Clostridium difficile Clostridium • The genus Clostridium is extremely heterogeneous, and more than 200 species have been described. • Most clostridia are harmless saprophytes, but some are well-recognized human pathogens. • They are obligate anaerobes capable of producing endospores. Most species grow only in the complete absence of oxygen. Clostridium • Clostridium are found in soil, water, and the intestinal tracts of humans and other animals. • They cause several important toxin-mediated diseases. • The major toxins produced by the species are neurotoxins affecting nervous tissue, histotoxins affecting soft tissue and enterotoxins affecting the gut. Clostridium • Clostridium grows in anaerobic conditions; Bacillus grows in aerobic conditions. • Clostridium forms bottle-shaped endospores; Bacillus forms oblong endospores. • Clostridium does not form the enzyme catalase; Bacillus secretes catalase to destroy toxic by-products of oxygen metabolism. Clostridium • Clostridia can ferment a variety of sugars; many can digest proteins. These metabolic characteristics are used to divide the Clostridia into groups, saccharolytic or proteolytic. • Many clostridia produce a zone of β-hemolysis on blood agar. • C. perfringens characteristically produces a double zone of β- hemolysis around colonies. Anaerobic culture of Clostridium perfringens on blood agar https://www.pinterest.es/pin/291326669631450707/ Clostridium • Clostridium tetani is the cause of tetanus • C. botulinum is the cause of botulism • C. perfringens, C. septicum, C. histolyticum and C. novyi are the causes of gas gangrene and other infections. • C. perfringens is also associated with a form of food poisoning. • C. difficile is the cause of pseudomembranous colitis and antibiotic-associated diarrhea.
    [Show full text]
  • Question of the Day Archives: Monday, December 5, 2016 Question: Calcium Oxalate Is a Widespread Toxin Found in Many Species of Plants
    Question Of the Day Archives: Monday, December 5, 2016 Question: Calcium oxalate is a widespread toxin found in many species of plants. What is the needle shaped crystal containing calcium oxalate called and what is the compilation of these structures known as? Answer: The needle shaped plant-based crystals containing calcium oxalate are known as raphides. A compilation of raphides forms the structure known as an idioblast. (Lim CS et al. Atlas of select poisonous plants and mushrooms. 2016 Disease-a-Month 62(3):37-66) Friday, December 2, 2016 Question: Which oral chelating agent has been reported to cause transient increases in plasma ALT activity in some patients as well as rare instances of mucocutaneous skin reactions? Answer: Orally administered dimercaptosuccinic acid (DMSA) has been reported to cause transient increases in ALT activity as well as rare instances of mucocutaneous skin reactions. (Bradberry S et al. Use of oral dimercaptosuccinic acid (succimer) in adult patients with inorganic lead poisoning. 2009 Q J Med 102:721-732) Thursday, December 1, 2016 Question: What is Clioquinol and why was it withdrawn from the market during the 1970s? Answer: According to the cited reference, “Between the 1950s and 1970s Clioquinol was used to treat and prevent intestinal parasitic disease [intestinal amebiasis].” “In the early 1970s Clioquinol was withdrawn from the market as an oral agent due to an association with sub-acute myelo-optic neuropathy (SMON) in Japanese patients. SMON is a syndrome that involves sensory and motor disturbances in the lower limbs as well as visual changes that are due to symmetrical demyelination of the lateral and posterior funiculi of the spinal cord, optic nerve, and peripheral nerves.
    [Show full text]
  • Large Scale Recovery of Tetanus Toxin and Toxoid from Fermentation Broth by Microporous Tangential Flow Filtration
    International Journal for Biotechnology and Molecular Biology Research Vol. 4(2), pp. 28-37, May, 2013 Available online http://www.academicjournals.org/IJBMBR DOI: 10.5897/IJBMBR12.014 ISSN 2141-2154 ©2013 Academic Journals Full Length Research Paper Large scale recovery of tetanus toxin and toxoid from fermentation broth by microporous tangential flow filtration Chellamani Muniandi 1*, Kavaratty Raju Mani 1 and Rathinasamy Subashkumar 2 1Pasteur Institute of India, Coonoor-643 103, The Nilgiris, Tamil Nadu, India. 2PG and Research Department of Biotechnology, Kongunadu Arts and Science College, Coimbatore – 641 029, Tamil Nadu, India Accepted 8 February, 2013 The commercial production of purified tetanus toxoid mainly depends on the effective separation of the bacterial toxin and toxoid from large volumes of fermentation broth of Clostridium tetani (Harvard 49205) vaccine strain. Tangential flow or cross-flow filtration system was used as rapid drive in the processing of immunobiological assays of tetanus toxin. Tetanus toxoid was prepared by detoxifying the culture filtrates of C. tetani and further purified by ultrafiltration, salt fractionation and adsorption onto aluminium phosphate. Present study deals with the separation of tetanus toxins using a microporous membrane (0.22 µm) and concentration of tetanus toxoids using an ultrafiltration membrane (30 kDa, NMWL pore size) with operational variables like average trans-membrane pressure (ATP), cross flow rate, flux. Under the best conditions, >96% recovery was achieved. Additionally, potency control of 10 batches of tetanus toxoid, prepared from the filtered toxins/toxoid lots by microporous tangential flow filtration system, was evaluated by in vitro passive haemagglutination (PHA) assay and the results obtained in the in vitro PHA were compared with in vivo toxin neutralization (TN) test.
    [Show full text]
  • Effect of Tetanus Toxin on Extracellular Levels of Neuroactive Amino Acids and Monoamines in Rat Hippocampus
    Effect of tetanus toxin on extracellular levels of neuroactive amino acids and monoamines in rat hippocampus By Paul Britton B.Sc. (Hons.) A thesis submitted in partial fulfilment for the Degree of Doctor of Philosophy in the Faculty of Science University of London Department of Pharmacology The School of Phamiacy 29-39 Brunswick Square London WCIN lAX ProQuest Number: U549764 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest. ProQuest U 549764 Published by ProQuest LLC(2016). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. Microform Edition © ProQuest LLC. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 Abstract The effect of the neurotoxin tetanus toxin, unilaterally injected into the ventral hippocampal formation, on extracellulai' levels of neuroactive amino acids and monoamines was investigated in rats using intracerebral microdialysis. A single dose (1000 mouse minimum lethal doses) of tetanus toxin did not alter extracellular levels of aspartate, glutamate, and taurine 1, 2, 3, and 7 days after treatment. However, whilst extracellular GAB A levels were unaffected by toxin injection 1, 2, and 3 days after treatment, they were reduced (45% of contralateral vehicle injected level) at day 7. Toxin treatment caused a progressive decline in extracellular 5-hydroxytryptamine levels over the first 3 days of dialysis (20% of contralateral control level at day 3), and a 65% reduction 7 days after injection.
    [Show full text]
  • Chemical Strategies to Target Bacterial Virulence
    Review pubs.acs.org/CR Chemical Strategies To Target Bacterial Virulence † ‡ ‡ † ‡ § ∥ Megan Garland, , Sebastian Loscher, and Matthew Bogyo*, , , , † ‡ § ∥ Cancer Biology Program, Department of Pathology, Department of Microbiology and Immunology, and Department of Chemical and Systems Biology, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, California 94305, United States ABSTRACT: Antibiotic resistance is a significant emerging health threat. Exacerbating this problem is the overprescription of antibiotics as well as a lack of development of new antibacterial agents. A paradigm shift toward the development of nonantibiotic agents that target the virulence factors of bacterial pathogens is one way to begin to address the issue of resistance. Of particular interest are compounds targeting bacterial AB toxins that have the potential to protect against toxin-induced pathology without harming healthy commensal microbial flora. Development of successful antitoxin agents would likely decrease the use of antibiotics, thereby reducing selective pressure that leads to antibiotic resistance mutations. In addition, antitoxin agents are not only promising for therapeutic applications, but also can be used as tools for the continued study of bacterial pathogenesis. In this review, we discuss the growing number of examples of chemical entities designed to target exotoxin virulence factors from important human bacterial pathogens. CONTENTS 3.5.1. C. diphtheriae: General Antitoxin Strat- egies 4435 1. Introduction 4423 3.6. Pseudomonas aeruginosa 4435 2. How Do Bacterial AB Toxins Work? 4424 3.6.1. P. aeruginosa: Inhibitors of ADP Ribosyl- 3. Small-Molecule Antivirulence Agents 4426 transferase Activity 4435 3.1. Clostridium difficile 4426 3.7. Bordetella pertussis 4436 3.1.1. C.
    [Show full text]
  • Acanthophis, Distribution Of, 2 Action Potential (Cont.) Acanthophis
    Index Acanthophis, distribution of, 2 action potential (cont.) Acanthophis antarticus tetrodotoxin and, 148, 170-176, venom, antivenin to, 14 191-193 venom, nerve activity of, II7 transmitter release by, 195-204 venom, systemic activity of, 8 Agkistrodon acutus, venom, systemic acetylcholine actions of, 99-101 botulinum toxin and, 312-314, Agkistrodon halys, venom, com- 317 ponents of, 98 metabolism of, 126-133, 326- Agkistrodon halys blomhoffi 327 venom, components of, 88, 92, neuromuscular transmission 104 and, 326-327 venom, systemic actions of, 105 nerve conduction and, 115 Agkistrodon mokeson nerve permeability and, 121-123 venom, local action of, 83 receptor to, 119-120, 327 venom, nervous action of, II7 tetanus toxin and, 271 Agkistrodon piscivorus tetrodotoxin and, 147, 176-177 venom, components of, 88 supersensitivity to, 312, 330-336 venom, distribution of, 95 acetylcholinesterase venom, local action of, 83 botulinum toxin and, 313, 336- venom, systemic action of, 95, 339 102, 105 cobra venom and, 32 Agkistrodon piscivorus piscivorus colubrid venom and, 125 venom, nervous action of, 117 neuromuscular transmission venom, systemic action of, 94 and, 326-327 Agkistrodon rhodostoma nerve conduction and, 115 venom, components of, 92 nerve permeability and, 121-123 venom, systemic action of, 97- tetanus toxin and, 271 101, 105 tetrodotoxin and, 177 Alaska butter clam, saxitoxin from action potential 163, 165, 189 basis of, 170, 190-191 alkaline phosphatase, nerve con­ phospholipase A and, II4-115, duction and, 117 125 Ambystoma, tetrodotoxin
    [Show full text]